Corcept Therapeutics (CORT) Tops Q2 EPS by 2c
Get Alerts CORT Hot Sheet
Price: $22.21 -1.2%
EPS Growth %: +57.1%
Financial Fact:
Net loss and comprehensive loss: 2.59M
Today's EPS Names:
FRSB, DGICA, UXIN, More
EPS Growth %: +57.1%
Financial Fact:
Net loss and comprehensive loss: 2.59M
Today's EPS Names:
FRSB, DGICA, UXIN, More
Join SI Premium – FREE
Corcept Therapeutics (NASDAQ: CORT) reported Q2 EPS of $0.03, $0.02 better than the analyst estimate of $0.01. Revenue for the quarter came in at $19.7 million versus the consensus estimate of $18.36 million.
For earnings history and earnings-related data on Corcept Therapeutics (CORT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Gilead Sciences (GILD) Misses Q1 EPS by 288c
- Gaming and Leisure Properties (GLPI) Misses Q1 EPS by 6c
- SPS Commerce (SPSC) Tops Q1 EPS by 12c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!